Faeth Therapeutics grants CEO 398K options

Faeth Therapeutics, Inc. granted President and CEO Anand Kiran Parikh a performance-based stock option covering 398,018 shares of common stock at a $28.3700 exercise price, expiring in 2036.

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. granted President and CEO Anand Kiran Parikh a performance-based stock option covering 398,018 shares of common stock at a $28.3700 exercise price, expiring in 2036. The option vests only if a sustained $70.00 stock-price hurdle and time-and-service conditions are met. In a qualifying Change in Control where per-share consideration is at least $70.00, it vests in full; if the $70.00 hurdle is not achieved by the fourth anniversary of grant, or not deemed achieved in connection with a Change in Control, the option is forfeited.

Insider Trade Summary

Grant/Award: 398,018 shares

Grant/Award 1 txn

Insider Parikh Anand Kiran

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Stock Option (right to buy) F1, F2	398,018	$0.00	$0.00

Holdings After Transaction: Performance-Based Stock Option (right to buy) — 398,018 contracts (Direct)

Footnotes (2)

1. F1. Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.
2. F2. In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.

Key Figures

Option grant size: 398,018 shares Exercise price: $28.3700 per share Underlying common shares: 398,018 shares +2 more

5 metrics

Option grant size 398,018 shares Performance-based stock option awarded to President and CEO

Exercise price $28.3700 per share Conversion or exercise price of the performance-based stock option

Underlying common shares 398,018 shares Shares of common stock underlying the performance-based option

Stock Price Hurdle $70.00 per share Average closing price over any 30-day period required for vesting

Option expiration date 2036-07-20 Expiration date of the performance-based stock option grant

Key Terms

Performance-Based Stock Option, Stock Price Hurdle, Change in Control, Equity Incentive Plan

4 terms

Performance-Based Stock Option financial

"Represents a performance-based stock option that becomes exercisable, if at all, on the later of"

Stock Price Hurdle financial

"the average closing price of the Issuer's common stock over 30 days equals or exceeds $70.00, the Stock Price Hurdle"

Change in Control financial

"In the event of a Change in Control of the Issuer prior to the end of the Performance Period"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Equity Incentive Plan financial

"Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Faeth Therapeutics (FTH) report in this Form 4?

Faeth Therapeutics reported a grant of performance-based stock options to its President and CEO, Anand Kiran Parikh. The award covers 398,018 shares of common stock at a $28.3700 exercise price and is structured with stringent performance and service-based vesting conditions.

How many performance-based stock options were granted to the Faeth Therapeutics (FTH) CEO?

The CEO received a performance-based stock option covering 398,018 shares of Faeth Therapeutics common stock. These options are not immediately exercisable and only vest if both stock-price and time-and-service conditions are satisfied, otherwise the entire award can be forfeited.

What is the exercise price and expiration date of the Faeth Therapeutics (FTH) CEO option grant?

The option has a $28.3700 exercise price per share and expires on July 20, 2036. This long-dated option provides potential future upside but only if the vesting requirements tied to stock performance and continued service are ultimately met.

What stock-price hurdle must be met for the Faeth Therapeutics (FTH) option to vest?

Vesting requires the average closing price of Faeth’s common stock to reach at least $70.00 over any 30 consecutive days. This Stock Price Hurdle must be met in addition to a minimum one-year service requirement and overall performance period conditions.

How does a Change in Control affect the Faeth Therapeutics (FTH) CEO’s performance option?

If a Change in Control occurs and per-share consideration is at least $70.00, the performance hurdle is deemed achieved and the option vests in full immediately before closing. If the hurdle is not achieved or deemed achieved, the option is forfeited in its entirety.

What happens if Faeth Therapeutics (FTH) does not hit the $70 stock-price target within the performance period?

If the $70.00 Stock Price Hurdle is not achieved by the fourth anniversary of the grant date, the performance-based option is forfeited. This means the CEO would receive no shares from this award if the hurdle and timing conditions are not satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:15 PM Accepted by SEC EDGAR 07/23/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Anand Kiran

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Stock Option (right to buy)	$28.37	07/21/2026		A		398,018		(1)(2)	07/20/2036	Common Stock	398,018	$0	398,018	D

Explanation of Responses:

1. Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.

2. In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.

	/s/ Josiah Craver, Attorney-in-Fact	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)